These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1944429)

  • 1. Hope for the treatment of intestinal scleroderma.
    Toskes PP
    N Engl J Med; 1991 Nov; 325(21):1508-9. PubMed ID: 1944429
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma.
    Soudah HC; Hasler WL; Owyang C
    N Engl J Med; 1991 Nov; 325(21):1461-7. PubMed ID: 1944424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Octreotide in intestinal pseudo-obstruction?].
    Layer P; Holtmann G
    Z Gastroenterol; 1992 May; 30(5):346-7. PubMed ID: 1632118
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
    Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
    Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Involvement of the small intestine during progressive systemic sclerosis. Presentation of a case and review of the literature].
    Papi A; Gonçalves CS; Arantes M; Perazzo S; Hércules HC; Santos JL; Pórto JA; Fraga Filho C
    Hospital (Rio J); 1968 Dec; 74(6):1779-98. PubMed ID: 5305606
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
    Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
    J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in upper gastrointestinal motility during scleroderma].
    Bassotti G; Betti C; Pelli MA; Morelli A
    Medicina (Firenze); 1990; 10(3):251-5. PubMed ID: 2079874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to consider medical therapy for small-bowel angioectasias.
    Gerson LB; Jackson C
    Am J Gastroenterol; 2012 Sep; 107(9):1442-3. PubMed ID: 22951882
    [No Abstract]   [Full Text] [Related]  

  • 9. [Syndromes of the changed transit of the small intestine].
    Barbara L
    Minerva Med; 1974 Feb; 65(11):571-80. PubMed ID: 4819394
    [No Abstract]   [Full Text] [Related]  

  • 10. [Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin].
    Lecomte T; Cavicchi M; Delchier JC
    Gastroenterol Clin Biol; 2000 Mar; 24(3):361-3. PubMed ID: 10804347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide in gastrointestinal motility disorders.
    Owyang C
    Gut; 1994; 35(3 Suppl):S11-4. PubMed ID: 8206395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small intestinal motility.
    Bratten JR; Jones MP
    Curr Opin Gastroenterol; 2007 Mar; 23(2):127-33. PubMed ID: 17268240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of small-bowel motor impairment in systemic sclerosis--a prospective manometric 5-yr follow-up.
    Marie I; Ducrotté P; Denis P; Hellot MF; Levesque H
    Rheumatology (Oxford); 2007 Jan; 46(1):150-3. PubMed ID: 16782730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global improvement of systemic scleroderma under long-term administration of octreotide.
    Descamps V; Duval X; Crickx B; Bouscarat F; Coffin B; Belaich S
    Eur J Dermatol; 1999 Sep; 9(6):446-8. PubMed ID: 10491499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Involvement of the small intestine in scleroderma].
    Kolár J; Drugová B; Stava Z
    Z Gastroenterol; 1972; 10(2):73-7. PubMed ID: 4671787
    [No Abstract]   [Full Text] [Related]  

  • 16. Intestinal perforation associated with octreotide therapy in scleroderma.
    Malcolm A; Ellard K
    Am J Gastroenterol; 2001 Nov; 96(11):3206-8. PubMed ID: 11721779
    [No Abstract]   [Full Text] [Related]  

  • 17. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases.
    Perlemuter G; Cacoub P; Chaussade S; Wechsler B; Couturier D; Piette JC
    Arthritis Rheum; 1999 Jul; 42(7):1545-9. PubMed ID: 10403284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudo-obstruction and other obstructive disorders.
    Snape WJ
    Clin Gastroenterol; 1982 Sep; 11(3):593-608. PubMed ID: 6754172
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe intestinal pseudoobstruction in a patient with systemic sclerosis. Successful treatment with octreotide.
    Lanting PJ; Kruijsen MW; Rasher JJ; van den Hoogen FH; Boerbooms AM; van de Putte LB
    J Rheumatol; 1993 Dec; 20(12):2175. PubMed ID: 8014959
    [No Abstract]   [Full Text] [Related]  

  • 20. Scleroderma with intestinal involvement: fatal in two of a kindred.
    Strosberg JM; Peck B; Harris ED
    J Rheumatol; 1977; 4(1):46-52. PubMed ID: 886552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.